

+

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number	09/715,965
Filing Date	November 17, 2000
First Named Inventor	Denholm
Group Art Unit	1651
Examiner Name	Meller, M.
Attorney Docket Number	IT 106 (CPA)

Sheet	1	of	5
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examine
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

09/715,965

Filing Date

November 17, 2000

First Named Inventor

Denholm

Group Art Unit

1651

Examiner Name

Meller, M.

Attorney Docket Number

IT 106 (CPA)

Sheet

2

of

5

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MM		CRUM, et al., "A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment," <i>Science</i> 230(4732): 1375-1378 (1985).	
		CULP, et al., "Two functionally distinct pools of glycosaminoglycan in the substrate adhesion site of murine cells," <i>J. Cell Biol.</i> 79(3):788-801 (1978).	
		DENHOLM, et al., "The effects of bleomycin on alveolar macrophage growth factor secretion," <i>Am J Pathol.</i> 134(2):355-63 (1989).	
		DENHOLM, et al., "Chondroitinase AC inhibits tumor cell invasion, proliferation, and angiogenesis," <i>FASEB J</i> 14(4): A702 (2000).	
		DENHOLM, et al., "Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion," <i>Eur J Pharmacol</i> 416(3): 213-221 (20001).	
		FAASSEN, et. al., "A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion," <i>J. Cell Biol.</i> 116(2):521-531 (1992).	
		FAASSEN, et. al., "Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type I collagen," <i>J. Cell Science</i> 105(Pt 2):501-511 (1993).	
		FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nat Med</i> 1(1):27-31 (1995).	
		FOLKMAN, "Successful treatment of an angiogenic disease," <i>N. Engl. J. Med.</i> 320(18): 1211-1212 (1989).	
		FOLKMAN, "Tumor angiogenesis: therapeutic implications," <i>N. Engl. J. Med.</i> 285(21): 1182-1186 (1971).	

Examiner's
Signature

Date Considered

9/13/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

09/715,965

Filing Date

November 17, 2000

First Named Inventor

Denholm

Group Art Unit

1651

Examiner Name

Meller, M.

Attorney Docket Number

IT 106 (CPA)


Sheet

3

of

5

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FOLKMAN, et al., "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," <i>Science</i> 221(4612): 719-725 (1983).	
		FOLKMAN, et al., "Control of angiogenesis with synthetic heparin substitutes," <i>Science</i> 243(4897): 1490-1493 (1989).	
		FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," <i>J. Am. Coll. Cardiol.</i> 17(3):758-769 (1991).	
		GU, et. al., "Purification, characterization and specificity of chondroitin lyases and glycuronidase from <i>Flavobacterium heparinum</i> ," <i>Biochem. J.</i> 312(Pt 2):569-577 (1995).	
		HENKE, et. al., "CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix," <i>J. Clin. Invest.</i> 97(11):2541-2552 (1996).	
		INGBER, et al., "Inhibition of angiogenesis through modulation of collagen metabolism," <i>J. Lab. Invest.</i> 59: 44-51 (1989).	
		INGBER, et al., "A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution," <i>Endocrinol.</i> 119(4): 1768-1775 (1986).	
		INGBER, et al., "Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix," <i>J. Cell. Biol.</i> 109(1): 317-330 (1989).	
		JACKSON et. al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," <i>Physiol. Rev.</i> 71(2):481-530 (1991).	
		JIN-INCHI, et al., "Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action," <i>Cancer Res.</i> 50:6731-6737 (1990).	

Examiner's Signature

[Signature]

Date Considered

9/13/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number

09/715,965

Filing Date

November 17, 2000

First Named Inventor

Denholm

Group Art Unit

1651

Examiner Name

Meller, M.

Attorney Docket Number

IT 106 (CPA)

RECEIVED
AUG 09 2002
TECH CENTER 1800/2800

Sheet 4 of 5

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MM		LIDA, et al., "Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion," <i>Sem. Cancer Biol.</i> 7:155-162, (1996).	
		LINHARDT, et al., "Polysaccharide lyases," <i>Appl. Biochem. Biotech.</i> 12(2): 135-176 (1986).	
		LINN et. al., "Isolation and characterization of two chondroitin lyases from <i>Bacteroides thetaiotaomicron</i> ," <i>J. Bacteriol.</i> 156(2):859-866 (1983).	
		MEYER, et al., "Mechanisms of tumour metastasis," <i>Eur. J. Cancer</i> 34(2):214-221 (1998).	
		MICHELACCI, et al., "Isolation and characterization of an induced chondroitinase ABC from <i>Flavobacterium heparinum</i> ," <i>Biochim. Biophys. Acta.</i> 923(2):291-301 (1987).	
		MURRAY, et al., "Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor," <i>J. Biol. Chem.</i> 261(9): 4154-4159 (1986).	
		NAKAJIMA, et al., "Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines," <i>Science</i> 220(4597):611-613 (1983).	
		RICHARDSON, et al., "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," <i>Exp. Mol. Pathol.</i> 58(2):77-95 (1993).	
		SATO, et al., "Submit structure of Chondroitinase ABC from <i>Proteus vulgaris</i> ," <i>Agric. Biol. Chem.</i> 50:1057-1059 (1986).	
✓		TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," <i>J. Biol. Chem.</i> 268(27):20419-20432 (1993).	

Examiner's Signature

Date Considered

9/13/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

09/715,965

Filing Date

November 17, 2000

First Named Inventor

Denholm

Group Art Unit

1651

Examiner Name

Meller, M.

Attorney Docket Number

IT 106 (CPA)

Sheet

5

of

5

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>[Signature]</i>		TAKEUCHI, "Effect of chondroitinases on the growth of solid Ehrlich ascites tumour," <i>Brit J Cancer</i> 26(2): 115-119 (1972).	
<i>[Signature]</i>		TROCHAN, et al., "Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro," <i>Int. J. Cancer</i> 66:664-668 (1996).	
<i>[Signature]</i>		VOLPI, "Fast moving and slow moving heparins, dermatan sulfate, and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis," <i>Carbohydrate Res.</i> 247:263-278 (1993).	
<i>[Signature]</i>		YEO, et al., "Alterations in proteoglycan synthesis common to healing wounds and tumors," <i>Am. J. Pathol.</i> 138(6):1437-1450 (1991).	
<i>[Signature]</i>		ZAWADZKI, et al., "Blockade of metastasis formation by CD44-receptor globulin," <i>Int. J. Cancer</i> 75(6):919-924 (1998).	

Examiner's Signature

[Handwritten Signature]

Date Considered

9/13/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+